Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $70K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $95K.

Context

  • Cost of revenue amounted to 7.4% of revenue in FY2025.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $70K or moves back toward the trailing-twelve-month quarterly average of $23.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$70K— QoQ
Last fiscal yearDec 2025
$114K— YoY
LTMMar 2026
$95K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
114K USD
Year-over-year change
—

Cost of Revenue vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 5.3% of revenue for MIST, versus a peer median of 5.1%.
MIST Competitors
Cost of Revenue for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding MIST) —-83.8%-30.4%5.1%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15M5M1M01.55M
Cost of Revenue0000114K
Gross Profit15M5M1M01.43M
Gross Margin100.0%100.0%100.0%—92.6%
Research & Development38.67M39.83M31.05M14.36M18.11M
Selling, General & Admin19.4M24.81M31.05M27.75M17.27M
Operating Expenses58.07M64.64M62.1M42.1M63.92M
Depreciation & Amortization93K89K92K105K114K
EBITDA(42.76M)(58.3M)(57.04M)(37.83M)(59.45M)
EBITDA Margin-285.1%-1166.0%-5703.9%—-3845.5%
Operating Income(43.07M)(59.64M)(61.1M)(42.1M)(62.49M)
Operating Margin-287.2%-1192.8%-6109.8%—-4041.7%
Interest Income220K1.25M3.97M4.16M2.92M
Interest Expense002.55M(3.58M)3.84M
Other Income / Expenses220K1.25M1.41M583K(918K)
Income Before Tax(42.85M)(58.39M)(59.69M)(41.52M)(63.4M)
Pre-Tax Margin-285.7%-1167.8%-5968.5%—-4101.1%
Income Tax Expense0000(345K)
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Net Margin-285.7%-1167.8%-5968.5%—-4078.8%
EPS (Basic)(1.02)(1.35)(1.39)(0.67)(0.75)
EPS (Diluted)(1.02)(1.35)(1.39)(0.67)(0.75)
Weighted Avg Shares41.83M42.45M42.96M62.21M83.88M
Weighted Avg Shares (Diluted)41.83M42.45M42.96M62.21M83.88M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.